Bin S. Teh VIEW CLINICAL PROFILE

Bin S. Teh, MD, FACR, FASTRO, FACRO

Professor of Radiation Oncology, Academic Institute
Full Member, Research Institute
Jim and Joan Harrell Centennial Chair in Radiation Oncology, Houston Methodist
Weill Cornell Medical College


VIEW CLINICAL PROFILE
Biography

Dr. Teh is a professor and vice chair of the Department of Radiation Oncology at Houston Methodist Hospital and Weill Medical School of Cornell. Dr. Teh has contributed significantly to the field of radiation oncology – encompassing radiotherapy technology, radiation physics, molecular radiobiology and the translation of advances in these areas to clinical use. He has been instrumental in pioneering new technology in radiation oncology including APBI (accelerated partial breast irradiation), IMRT (intensity-modulated radiation therapy), IGRT (image-guided radiation therapy), SBRT (stereotactic body radiation therapy), SRS (stereotactic radiosurgery), brachytherapy as well as combined radiotherapy and gene therapy. Dr. Teh treated the first breast cancer patient in Houston with multi-lumen catheter (Contura) high dose rate brachytherapy for partial breast irradiation. This is a short course of five days irradiation, as compared to the conventional six weeks irradiation for breast cancer. Partial breast irradiation is a novel approach to spare more normal tissues.

Dr. Teh earned his medical degree from the University of Queensland in Queensland, Australia. He completed his Radiation Oncology residency, training and fellowship in IMRT at the Baylor College of Medicine in Houston, Texas. Dr. Teh is active in ASTRO (American Society of Therapeutic Radiology and Oncology), RSNA (Radiological Society of North America and ARS (American Radium Society). He is the principal investigator for RTOG (Radiation Therapy Oncology Group) at Houston Methodist Hospital. Dr. Teh has published more than 100 peer-reviewed articles on topics such as IMRT for breast cancer, editorials, 15 book chapters and a textbook on PET-CT in radiotherapy. He plays an important role in breast cancer patient care, clinical research and the education of residents and students.

Description of Research

Dr. Teh’s research focuses on the treatment of genito-urinary malignancies and unlocking the myth of radio-resistance in cancers especially renal cell carcinoma. Other research interests include Intensity modulated radiation therapy (IMRT) for prostate cancer, head and neck cancer, central nervous system tumor, pediatric cancer and breast cancer, stereotactic radiosurgery (SRS), stereotactic body radiotherapy (SBRT), stereotactic radiation therapy (SRT) and image-guided radiation therapy (IGRT), brachytherapy for prostate cancer, breast cancer and endobronchial tumors, SRS and SBRT for primary and metastatic renal cell carcinoma as well as hepatocellular carcinoma, the role of combined radiotherapy and gene therapy for cancers including prostate cancer, renal cell carcinoma, bladder cancer, pancreatic cancer, glioblastoma multiforme, cervical cancer and head and neck cancer, combining targeted therapy (AKT-inhibitor, mTOR inhibitor, tyrosine kinase inhibitor) with radiotherapy for cancer treatment, and combining oncolytic virus with radiotherapy in overcoming radio-resistant tumors in oncology.

Areas Of Expertise

Cancer stem cells Radio-resistance Prostate Movement study Post-prostatectomy IMRT Gene expression profiling in cancer Proteomics in oncology
Education & Training

Residency, Baylor College of Medicine
Clinical Fellowship, Baylor College of Medicine
MD, University of Queensland
Publications

Comparative real-world survival outcomes of muscle-invasive bladder cancer treated with bladder-only vs. whole-pelvis concurrent chemoradiation
Riveros, C, Ranganathan, S, Haque, W, Huang, E, Xu, J, Kulkarni, GS, Geng, M, Anis, M, Muhammad, T, Chan, KS, Farach, A, Teh, BS, Miles, BJ, Klaassen, Z, Sonpavde, GP, Wallis, CJD & Satkunasivam, R 2024, , Journal of the Canadian Urological Association, vol. 18, no. 2, pp. 17-24. https://doi.org/10.5489/cuaj.8386

Radiation Pneumonitis, Really? A Case of Pulmonary Toxicity from CDK4/6 Inhibitor
Hunt, A, Haque, W, Pino, R, Farach, A, Butler, EB & Teh, BS 2023, , Anticancer Research, vol. 43, no. 8, pp. 3539-3542. https://doi.org/10.21873/anticanres.16531

The Judicious Use of Stereotactic Ablative Radiotherapy in the Primary Management of Localized Renal Cell Carcinoma
Barbour, AB, Kirste, S, Grosu, AL, Siva, S, Louie, AV, Onishi, H, Swaminath, A, Teh, BS, Psutka, SP, Weg, ES, Chen, JJ, Zeng, J, Gore, JL, Hall, E, Liao, JJ, Correa, RJM & Lo, SS 2023, , Cancers, vol. 15, no. 14, 3672. https://doi.org/10.3390/cancers15143672

Overview of late complications of radiation therapy in uveal melanoma
Wong, AJ, Schefler, AC & Teh, BS 2023, , Chinese Clinical Oncology, vol. 12, no. 3, 29, pp. 29. https://doi.org/10.21037/cco-22-88

Focal versus whole gland salvage brachytherapy for recurrent prostate cancer in the prostate specific membrane antigen PET era: a narrative review
Andring, LM, Teh, BS, Butler, EB & Farach, AM 2023, , Chinese Clinical Oncology, vol. 12, no. 3, 26, pp. 26. https://doi.org/10.21037/cco-23-4

Prognostic impact of biologically equivalent dose in stereotactic body radiotherapy for renal cancer
Tran, KT, Chevli, NC, Messer, JA, Haque, W, Farach, AM, Satkunasivam, R, Zhang, J, Darcourt, J, Lo, SS, Siva, S, Butler, EB & Teh, BS 2023, , Clinical and Translational Radiation Oncology, vol. 39, 100592, pp. 100592. https://doi.org/10.1016/j.ctro.2023.100592

Long term outcomes in older patients with primary central nervous system lymphoma: an analysis of the Texas Cancer Registry
Burns, EA, Sanchez, CG, Mathur, S, Guerrero, C, Muhsen, IN, Sarfraz, H, Hu, CCA, Tang, CHA, Shah, SS, Tremont, IW, Teh, B, Ganguly, S & Pingali, SRK 2023, , Annals of Hematology, vol. 102, no. 5, pp. 1111-1120. https://doi.org/10.1007/s00277-023-05140-6

A Phase 2 Study of In Situ Oncolytic Virus Therapy and Stereotactic Body Radiation Therapy Followed by Pembrolizumab in Metastatic Non-Small Cell Lung Cancer
Guan, J, Sun, K, Guerrero, CA, Zheng, J, Xu, Y, Mathur, S, Teh, BS, Farach, A, Zhang, J, Butler, E, Pan, PY, Zsigmond, E, Mei, Z, Mejia, J, Chen, SH, Chang, JC & Bernicker, EH 2023, , International Journal of Radiation Oncology Biology Physics, vol. 118, no. 5, pp. 1531-1540. https://doi.org/10.1016/j.ijrobp.2023.08.044

5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)
Siva, S, Ali, M, Correa, RJM, Muacevic, A, Ponsky, L, Ellis, RJ, Lo, SS, Onishi, H, Swaminath, A, McLaughlin, M, Morgan, SC, Cury, FL, Teh, BS, Mahadevan, A, Kaplan, ID, Chu, W, Grubb, W, Hannan, R, Staehler, M, Warner, A & Louie, AV 2022, , The Lancet Oncology, vol. 23, no. 12, pp. 1508-1516. https://doi.org/10.1016/S1470-2045(22)00656-8

Comparison of Tumor Size and Gene Expression at Presentation in Uveal Melanoma Patients before and during the COVID-19 Pandemic
Hasegawa, N, Rusakevich, A, Bernicker, E, Teh, BS & Schefler, A 2022, , Ocular Oncology and Pathology, vol. 8, no. 3, pp. 156-160. https://doi.org/10.1159/000524918

A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
Mathur, SK, Sun, K, Chang, JC, Niravath, PA, Darcourt, J, Patel, T & Teh, BS 2022, , Clinical Cancer Research, vol. 28, no. 20, pp. 4392-4401. https://doi.org/10.1158/1078-0432.CCR-22-0622

Prognostic Impact of Radiation Therapy in Pure Mucinous Breast Carcinoma
Chevli, N, Wang, K, Haque, W, Schwartz, MR, Nangia, J, Sasaki, J, Farach, AM, Hatch, SS, Butler, EB & Teh, BS 2022, , Clinical Breast Cancer, vol. 22, no. 7, pp. e807-e817. https://doi.org/10.1016/j.clbc.2022.06.005

21-Gene recurrence score predictive for prognostic benefit of radiotherapy in patients age = 70 with T1N0 ER/PR + HER2- breast cancer treated with breast conserving surgery and endocrine therapy
Chevli, N, Haque, W, Tran, KT, Farach, AM, Schwartz, MR, Hatch, SS, Butler, EB & Teh, BS 2022, , Radiotherapy and Oncology, vol. 174, pp. 37-43. https://doi.org/10.1016/j.radonc.2022.06.013

A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible MIBC: The RAD VACCINE MIBC trial
Satkunasivam, R, Lim, K, Teh, BS, Guzman, J, Zhang, J, Farach, A, Chen, SH, Wallis, CJD, Efstathiou, E, Esnaola, NF & Sonpavde, GP 2022, , Future Oncology, vol. 18, no. 25, pp. 2771-2781. https://doi.org/10.2217/fon-2022-0380

Contemporary trends in management of uveal melanoma
Chevli, N, Zuhour, RJ, Messer, JA, Haque, W, Schefler, AC, Bernicker, EH, Chevez-Barrios, P, Farach, AM, Butler, EB & Teh, BS 2022, , Journal of Contemporary Brachytherapy, vol. 14, no. 2, pp. 123-129. https://doi.org/10.5114/jcb.2022.115210

Three-year outcomes of uveal melanoma treated with intra-operative ultrasound-guided iodine-125 brachytherapy using custom-built eye plaques
Wong, AJ, Teh, BS, Nguyen, BT, Pino, R, Bretana, ME, Bernicker, EH, Chevez-Barrios, P, Butler, EB & Schefler, AC 2022, , Journal of Contemporary Brachytherapy, vol. 14, no. 2, pp. 130-139. https://doi.org/10.5114/jcb.2022.115379

Prognostic and predictive impact of MGMT promoter methylation status in high risk grade II glioma
Haque, W, Teh, C, Butler, EB & Teh, BS 2022, , Journal of Neuro-Oncology, vol. 157, no. 1, pp. 137-146. https://doi.org/10.1007/s11060-022-03955-3

Neoadjuvant Chemotherapy for Metaplastic Breast Cancer: Response Rates, Management, and Outcomes
Haque, W, Verma, V, Schwartz, MR, Lim, B, Mangalampalli, N, Butler, EB & Teh, BS 2022, , Clinical Breast Cancer, vol. 22, no. 5, pp. e691-e699. https://doi.org/10.1016/j.clbc.2022.01.006

Clinical factors and association with treatment modalities in patients with breast cancer and brain metastases who develop leptomeningeal metastases
Puri, A, Mylavarapu, C, Xu, J, Patel, TA, S.Teh, B, Tremont-Lukats, I, Chang, JC & Niravath, P 2022, , Breast Cancer Research and Treatment, vol. 193, no. 3, pp. 613-623. https://doi.org/10.1007/s10549-022-06595-3

A feasibility study of utilizing a cadaveric training model for novel robotic bladder cancer brachytherapy techniques
Patel, A, Orakwue, CW, Olek, D, Guzman, JCA, Lim, K, Pino, R, Teh, BS, Butler, B, Satkunasivam, R & Farach, A 2023, , Brachytherapy, vol. 22, no. 2, pp. 195-198. https://doi.org/10.1016/j.brachy.2022.08.014

VIEW FULL PUBLICATIONS